Michelle Glass
#129,848
Most Influential Person Now
New Zealand pharmacology academic
Michelle Glass's AcademicInfluence.com Rankings
Michelle Glassmedical Degrees
Medical
#2500
World Rank
#2927
Historical Rank
Pharmacology
#366
World Rank
#417
Historical Rank
Download Badge
Medical
Michelle Glass's Degrees
- PhD Pharmacology University of Auckland
- Masters Pharmacology University of New Zealand
Why Is Michelle Glass Influential?
(Suggest an Edit or Addition)According to Wikipedia, Michelle Glass is a New Zealand pharmacology academic. She is currently a full professor and Head of the Department of Pharmacology & Toxicology at the University of Otago. Career Since a 1994 PhD titled 'Receptor alterations in human neuro-degenerative diseases' at the University of Auckland, she has worked at both the University of Auckland and the University of Otago, rising to full professor.
Michelle Glass's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain (1997) (969)
- Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a Gs Linkage to the CB1 Receptor (1997) (638)
- Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. (2000) (555)
- The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease (2000) (531)
- Cannabinoid receptors and their endogenous agonists. (1998) (379)
- Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Enhances Heterodimer Formation: A Mechanism for Receptor Cross-Talk? (2005) (359)
- Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. (1999) (307)
- The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. (2007) (262)
- LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. (1998) (229)
- Meta‐analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences (2007) (220)
- Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity (2017) (216)
- Loss of cannabinoid receptors in the substantia nigra in huntington's disease (1993) (214)
- Cannabis, cannabinoids and reproduction. (2004) (189)
- Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. (2016) (183)
- Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. (2015) (170)
- CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. (2002) (165)
- The endocannabinoid system as a target for the treatment of neurodegenerative disease (2010) (157)
- Evolutionary origins of the endocannabinoid system. (2006) (155)
- Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. (2015) (154)
- Optical Rotatory Dispersion Associated with Dissymmetric Non-conjugated Chromophores. An Extension of the Octant Rule1-3 (1962) (150)
- The Stereochemistry of Doubly Bridged Biphenyls: Synthesis, Spectral Properties, and Optical Stability (1964) (146)
- Cannabinoid CB1 and CB2 Receptor Signaling and Bias (2017) (144)
- Delayed onset of huntington′s disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors (2004) (132)
- Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! (2008) (129)
- Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain (2007) (126)
- Loss of A1 adenosine receptors in human temporal lobe epilepsy (1996) (119)
- Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor (2015) (112)
- Configuratio, Conformation and Rotatory Dispersion of Optically Active Biaryls (1962) (107)
- Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease (2009) (105)
- A new cannabinoid CB2 receptor agonist HU‐910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury (2012) (98)
- Neurochemical and morphological changes associated with human epilepsy (1995) (98)
- Cannabinoid receptors are absent in insects (2001) (91)
- Real‐time characterization of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action (2013) (87)
- Cannabinoid (CB1), GABAA and GABAB receptor subunit changes in the globus pallidus in Huntington's disease (2009) (86)
- Characterization of the endocannabinoid system in early human pregnancy. (2004) (81)
- The role of Cannabinoids in neurodegenerative diseases (2001) (76)
- Differential activation of G‐proteins by μ‐opioid receptor agonists (2006) (76)
- Modulation of Neurotransmission by Cannabinoids in the Basal Ganglia (1997) (74)
- The synthesis and pharmacological evaluation of adamantane-derived indoles: cannabimimetic drugs of abuse. (2013) (74)
- Detailed Characterisation of CB2 Receptor Protein Expression in Peripheral Blood Immune Cells from Healthy Human Volunteers Using Flow Cytometry (2010) (73)
- Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. (2011) (71)
- Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice (2010) (69)
- Cannabinoid Receptors: A brief history and what not (2009) (69)
- Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease (2010) (68)
- Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. (2003) (68)
- Cannabinoid receptors in invertebrates (2006) (60)
- Functional mapping of cannabinoid receptor homologs in mammals, other vertebrates, and invertebrates. (2003) (58)
- Gαs signalling of the CB1 receptor and the influence of receptor number (2017) (57)
- Induction of Krox-24 by Endogenous Cannabinoid Type 1 Receptors in Neuro2A Cells Is Mediated by the MEK-ERK MAPK Pathway and Is Suppressed by the Phosphatidylinositol 3-Kinase Pathway* (2006) (57)
- GPR18 undergoes a high degree of constitutive trafficking but is unresponsive to N-Arachidonoyl Glycine (2016) (55)
- Cannabinoid Receptor 1 trafficking and the role of the intracellular pool: implications for therapeutics. (2010) (55)
- Allosteric Modulation of the Cannabinoid CB1 Receptor (2017) (55)
- Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism. (2008) (54)
- Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology (2011) (51)
- Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors (2020) (48)
- Affinity and Efficacy Studies of Tetrahydrocannabinolic Acid A at Cannabinoid Receptor Types One and Two (2017) (46)
- Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol. (2019) (44)
- A shifted repertoire of endocannabinoid genes in the zebrafish (Danio rerio) (2007) (44)
- Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence (2019) (42)
- Cannabinoid Receptor 2 (CB2) Signals via G-alpha-s and Induces IL-6 and IL-10 Cytokine Secretion in Human Primary Leukocytes (2019) (38)
- Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. (2018) (36)
- A novel population of progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain (2006) (36)
- Altered Amygdala Excitation and CB1 Receptor Modulation of Aggressive Behavior in the Neuroligin-3R451C Mouse Model of Autism (2018) (35)
- Induction of the Krox 24 transcription factor in striosomes by a cannabinoid agonist. (1995) (34)
- Control of Laser Damage in LiNbO3 (1973) (33)
- Localisation of the adenosine uptake site in the human brain: a comparison with the distribution of adenosine Al receptors (1996) (33)
- A NOVEL HIGH‐THROUGHPUT ASSAY FOR THE QUANTITATIVE ASSESSMENT OF RECEPTOR TRAFFICKING (2008) (32)
- The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities (2016) (30)
- Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain (2014) (29)
- Nuclear localisation of the endocannabinoid metabolizing enzyme fatty acid amide hydrolase (FAAH) in invasive trophoblasts and an association with recurrent miscarriage. (2008) (27)
- Do toxic synthetic cannabinoid receptor agonists have signature in vitro activity profiles? A case study of AMB-FUBINACA. (2019) (27)
- Misidentification of prostamides as prostaglandins Published, JLR Papers in Press, May 1, 2005. DOI 10.1194/jlr.C500006-JLR200 (2005) (27)
- A GENERALIZATION OF THE OCTANT RULE1 (1961) (26)
- Characterization of NTera2/D1 cells as a model system for the investigation of cannabinoid function in human neurons and astrocytes (2011) (26)
- Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy (2014) (26)
- Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors. (2015) (25)
- One for the Price of Two…Are Bivalent Ligands Targeting Cannabinoid Receptor Dimers Capable of Simultaneously Binding to both Receptors? (2016) (24)
- CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist (2019) (24)
- Identification of N‐arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors (2016) (23)
- Structure–activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues (2015) (23)
- High throughput quantification of mutant huntingtin aggregates (2008) (23)
- 100 years of modelling ligand–receptor binding and response: A focus on GPCRs (2020) (22)
- Simultaneous analysis of 29 synthetic cannabinoids and metabolites, amphetamines and cannabinoids in human whole blood by LC-MS/MS - A New Zealand perspective of use in 2018. (2020) (22)
- Functional Selectivity at Cannabinoid Receptors. (2017) (22)
- Anandamide receptor signal transduction. (2009) (21)
- Nematicidal effects of hemp (Cannabis sativa) may not be mediated by cannabinoid receptors (2001) (21)
- LY 320135 , a Novel Cannabinoid CB 1 Receptor Antagonist , Unmasks Coupling of the CB 1 Receptor to Stimulation of cAMP Accumulation 1 (1997) (20)
- Effects of the Parkinsonian toxin MPP+ on electrophysiological properties of nigral dopaminergic neurons. (2014) (20)
- Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. (2020) (19)
- CONFIGURATION AND OPTICAL ROTATORY DISPERSION OF ATROPISOMERIC BIARYLS1 (1960) (18)
- The therapeutic potential of G-protein coupled receptors in Huntington's disease. (2010) (16)
- Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines (2018) (15)
- Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists. (2020) (15)
- Model‐free and kinetic modelling approaches for characterising non‐equilibrium pharmacological pathway activity: Internalisation of cannabinoid CB1 receptors (2019) (14)
- Do you feel it now? Route of administration and Δ9-tetrahydrocannabinol-like discriminative stimulus effects of synthetic cannabinoids in mice. (2019) (14)
- Sulfation of the FLAG epitope is affected by co-expression of G protein-coupled receptors in a mammalian cell model (2016) (13)
- Misidentification of prostamides as prostaglandins (2005) (13)
- M1 Muscarinic Receptor Activation Mediates Cell Death in M1-HEK293 Cells (2013) (13)
- The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs. (2019) (13)
- Chromenopyrazole-based High Affinity, Selective Fluorescent Ligands for Cannabinoid Type 2 Receptor. (2019) (13)
- Real-Time Measurement of Cannabinoid Receptor-Mediated cAMP Signaling. (2017) (12)
- An evaluation of the operational model when applied to quantify functional selectivity (2018) (12)
- A MODEL FOR ANGLE STRAIN CALCULATIONS. OPTICALLY ACTIVE SYMMETRICALLY BRIDGED BIPHENYLS1,2 (1961) (12)
- Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment. (2017) (11)
- Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias (2021) (11)
- Exploring Stereochemical and Conformational Requirements at Cannabinoid Receptors for Synthetic Cannabinoids Related to SDB-006, 5F-SDB-006, CUMYL-PICA, and 5F-CUMYL-PICA. (2020) (11)
- Sensitive and Accurate Quantification of Human Leukocyte Migration Using High-Content Discovery-1 Imaging System and ATPlite Assay (2012) (10)
- Cannabinoid Receptor Signal Transduction Pathways (2009) (10)
- Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre (2020) (9)
- Is the Cannabinoid CB2 Receptor a Major Regulator of the Neuroinflammatory Axis of the Neurovascular Unit in Humans? (2017) (8)
- c-fos antisense reduces expression of Krox 24 in rat caudate and neocortex (1994) (7)
- Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1H)-one-3-carboxamide scaffold. (2018) (7)
- Increasing the flexibility of the LANCE cAMP detection kit. (2015) (7)
- In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018 (2020) (6)
- The Endocannabinoid System and Human Brain Functions: Insight From Memory, Motor, and Mood Pathologies (2017) (6)
- Development of 3-(4-Chlorophenyl)-1-(phenethyl)urea Analogues as Allosteric Modulators of the Cannabinoid Type-1 Receptor: RTICBM-189 is Brain Penetrant and Attenuates Reinstatement of Cocaine-Seeking Behavior. (2021) (6)
- A novel allosteric modulator of the cannabinoid CB1 receptor ameliorates hyperdopaminergia endophenotypes in rodent models (2020) (6)
- Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling (2020) (5)
- Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. (2022) (5)
- NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity? (2021) (5)
- Increased rate of routine second newborn screen in Washington state. (1996) (4)
- Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies (2021) (4)
- Divalent cannabinoid-1 receptor ligands: A linker attachment point survey of SR141716A for development of high-affinity CB1R molecular probes. (2019) (4)
- Co-exposure of cannabinoids with amphetamines and biological, behavioural and health outcomes: a scoping review of animal and human studies (2021) (3)
- Defining Steric Requirements at CB1 and CB2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. (2022) (3)
- Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. (2021) (3)
- An intact model for quantifying functional selectivity (2019) (3)
- Delineating the interactions between the cannabinoid CB2 receptor and its regulatory effectors; β‐arrestins and GPCR kinases (2021) (3)
- Development of positive control tissue for in situ hybridisation using Alvetex scaffolds (2014) (3)
- Cannabinoid mediated signal transduction (2002) (2)
- Inconsistencies in histone acetylation patterns among different HD model systems and HD post-mortem brains (2020) (2)
- Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (CaV3) Inhibitors. (2022) (2)
- Cannabis-based medicinal products in arthritis, a painful conundrum. (2020) (1)
- Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite (2022) (1)
- Development of Chromenopyrazole-Based Selective Cannabinoid 2 Receptor Agonists (2020) (1)
- The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogues (2018) (1)
- Exploring group size for statistical analysis of real‐time signalling experiments (2021) (1)
- Chapter 59 – Signaling and Regulation of the Cannabinoid CB1 Receptor (2017) (1)
- Neuroprotective activity of new Δ3-N-acylethanolamines in a focal ischemia stroke model. (2021) (1)
- INDUCTION OF KROX-24 BY ENDOGENOUS CB1 RECEPTORS IN NEURO2A CELLS IS MEDIATED BY THE MEK-ERK MAPK PATHWAY AND IS SUPPRESSED BY THE PI3K PATHWAY. (2006) (1)
- Cannabinoid 1 (CB1) receptor arrestin subtype‐selectivity and phosphorylation dependence (2022) (0)
- Synthesis and pharmacological evaluation of newly detected synthetic cannabinoid receptor agonists AB-4CN-BUTICA, MMB-4CN-BUTINACA, MDMB-4F-BUTICA, MDMB-4F-BUTINACA and their analogs (2022) (0)
- What is medicinal cannabis? (2019) (0)
- In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator? (2022) (0)
- The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism (2023) (0)
- An intact model for quantifying functional selectivity (2019) (0)
- The Role of Endocannabinoids in the Development, Progression, and Treatment of Neurodegenerative Diseases (2005) (0)
- Additions and Corrections - A Model for Angle Strain Calculations. Optically Active Symmetrically Bridged Biphenyls. (1962) (0)
- Covalent cannabinoid receptor ligands - structural insight and selectivity challenges. (2022) (0)
- 166 INTRATHECAL INJECTION OF A CANNABINOID CB2 RECEPTOR SELECTIVE AGONIST GW405833 BLOCKS INDUCTION OF ALLODYNIA BY SCIATIC INFLAMMATORY NEURITIS (SIN) (2009) (0)
- Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG‐018 (2022) (0)
- Doped CdTe; an optimized photorefractive semiconductor (1987) (0)
This paper list is powered by the following services:
Other Resources About Michelle Glass
What Schools Are Affiliated With Michelle Glass?
Michelle Glass is affiliated with the following schools:
